Plasmodium falciparum is a single celled parasite that causes the most deadly of the 4 kinds of human malaria. There is currently no vaccine to prevent this disease, and about 200 million people suffer from malaria each year. In fact, malaria causes 2 million deaths each year, most of them children in sub-Saharan Africa. There is an acute need for effective chemotherapeutic agents for prophylaxis and treatment of falciparum malaria. Drugs that target dihydrofolate reductase (DHFR), a key enzyme in the synthesis of deoxythymidine, histidine, and methionine and sulfonamides that target dihydropteroate synthase (DHPS), required for the synthesis of folate have been extremely effective in the past . In most cases, combinations of these drugs have been used, because the drugs act synergistically. However, the incredibly rapid selection of resistant P. falciparum populations has made the drugs virtually useless in many regions. The parasites are resistant to the drugs because they carry alleles of the DHFR or DHPS genes that encode mutant forms of the target enzyme.
The P. falciparum parasites can be grown in the lab, but their culture is expensive and labor intensive. To simplify study of these target enzymes from P. falciparum, we have engineered a series of strains of the budding yeast, Saccharomyces cerevisiae. These yeast lack endogenous DHFR or DHPS, but can grow because we have transformed them with the P. falciparum version of one of these enzymes. This approach has allowed us to use the yeast system to study the function of the parasite enzymes in a simple, inexpensive way. Normally, yeast are insensitive to antimalaria drugs, but these engineered yeast strains are now sensitive to inhibitors of the P. falciparum enzymes. We are studying the mutations in the DHFR and DHPS genes that confer resistance to inhibitors of these enzymes. We have used this approach to identify new mutations that can encode drug-resistant enzymes, and to screen a panel of potential new inhibitors for their effectiveness against the parasite enzymes. In addition, we have used the polymerase chain reaction to amplify DHFR genes from blood samples collected between 1984 and 1999 in Kenya. Yeast strains that express these alleles have been engineered, and used to characterize the drug sensitivity profiles of the parasites that infected these patients. These data are being used to reconstruct the history of the selection for drug-resistant alleles that has occurred since the introduction of Fansidar into use in Kenya.
We have two overall goals in our work. First, to use the basic techniques of genetics and molecular biology to understand the mechanism of inhibition of P. falciparum DHFR and DHPS by antifolate drugs. This will allow the design of alternative drugs that are effective against parasites that are resistant to currently available drugs. Second, to use this simple yeast system to understand the selection pressures that have resulted in mutations that confer drug resistance. We hope to apply this understanding to design deployment and use strategies that will slow the selection of drug-resistant parasites in the future.
pdb files of WR99210 analogues
Drug Resistance and Malaria
Spoke Assay Chart
Molecular Data on Chloroquine and Antifols Worldwide
Mutation Inventory Chart